Technical Articles

Fibroblast growth factor 23 (FGF-23) is an endocrine signaling protein secreted by osteocytes and osteoblasts, playing a central regulatory role in the pathological progression of chronic kidney disease-mineral and bone disorder (CKD-MBD).

The T cell receptor complex serves as the central regulatory hub of adaptive immune responses, and the precision of its signal transduction directly determines the fate choice between immune activation and tolerance.

Overview of the Molecular Structure and Biological Functions of the Prolactin Receptor.

The central role of IL-2 in immune regulation and the need for research tools.

The central role of CD3 target in therapeutic antibody development and the challenges of affinity window

The GDF-8 target, with its unique dual regulatory capabilities in muscle and metabolism, covers diverse fields of basic research including metabolism, aging, muscle injury, livestock breeding, and cancer cachexia. It has become a high-frequency research target in life science laboratories in recent years, with standardized research models and experimental protocols established for various scenarios.

Based on the molecular characteristics of GDF-8 inhibiting skeletal muscle growth, global pharmaceutical companies targeting GDF-8 drug development uniformly focus on blocking target signal transduction as the core logic. The current mainstream technical approaches are divided into three categories: neutralizing monoclonal antibodies, which specifically bind to mature GDF-8 ligands to block ligand-receptor binding; soluble ActRIIB fusion proteins (receptor traps), which rely on extracellular domains to capture circulating GDF-8 and activin A; and follistatin analogs, which mimic endogenous inhibitory molecules to competitively bind GDF-8 and inhibit pathway activation.

Growth differentiation factor 8, abbreviated as GDF-8, commonly known as Myostatin in the industry, belongs to the TGF-β superfamily of secreted proteins. It is currently a core and highly popular target in the field of skeletal muscle regulation and was first identified in 1997 by a research team from a mouse skeletal muscle cDNA library.

The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a key member of the class B1 G protein-coupled receptor family, forming a core receptor network with GLP-1R and GCGR to regulate glucose homeostasis and energy metabolism.

The glucagon-like peptide-1 receptor (GLP-1R) is an important member of the class B1 G protein-coupled receptor (GPCR) family and plays a key role in glucose homeostasis regulation. Since the first GLP-1 receptor agonist (GLP-1RA), exenatide, was approved for the treatment of type 2 diabetes in 2005, this target has become one of the most successful targets in the development of drugs for metabolic diseases.